252 related articles for article (PubMed ID: 22124372)
1. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
Trüe O; Matthias P
Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
[TBL] [Abstract][Full Text] [Related]
2. An overview of naturally occurring histone deacetylase inhibitors.
Kim B; Hong J
Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors and cell death.
Zhang J; Zhong Q
Cell Mol Life Sci; 2014 Oct; 71(20):3885-901. PubMed ID: 24898083
[TBL] [Abstract][Full Text] [Related]
4. The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration.
Mertsch S; Krämer OH
Cytokine Growth Factor Rev; 2017 Oct; 37():29-45. PubMed ID: 28606734
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
D'Mello SR
Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
[TBL] [Abstract][Full Text] [Related]
6. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
7. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
Saha RN; Pahan K
Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy.
Patra S; Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Mishra SR; Behera BP; Jena M; Bhutia SK
Cell Mol Life Sci; 2019 Sep; 76(17):3263-3282. PubMed ID: 30982077
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
11. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
Li G; Jiang H; Chang M; Xie H; Hu L
J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
[TBL] [Abstract][Full Text] [Related]
13. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires C; Zwick V; Nurisso A; Schenker E; Carrupt PA; Cuendet M
Mol Neurodegener; 2013 Jan; 8():7. PubMed ID: 23356410
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
[TBL] [Abstract][Full Text] [Related]
15. Human neuronal cells: epigenetic aspects.
Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of histone deacetylases (HDACs) in UPR regulation.
Kahali S; Sarcar B; Chinnaiyan P
Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
[TBL] [Abstract][Full Text] [Related]
18. Multiple roles of HDAC inhibition in neurodegenerative conditions.
Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Batchu SN; Brijmohan AS; Advani A
Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
Dietz KC; Casaccia P
Pharmacol Res; 2010 Jul; 62(1):11-7. PubMed ID: 20123018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
